James M.  Thorburn net worth and biography

James Thorburn Biography and Net Worth

Mr. Thorburn is a seasoned technology executive with more than 30 years of finance and operating experience in both private and public technology companies. Prior to Twist Bioscience, he served as Chief Sales Officer of Televerde, a demand generation and sales acceleration enterprise, focused on scaling the business internationally. Prior to Televerde, he served as interim CFO of several public and private companies including Enercore, Next Autoworks, Fisker Automotive and Numonyx (acquired by Micron). As interim CFO of Numonyx, he was responsible for coordination of the merger between ST Microelectronics and the Intel Flash Memory divisions as well as the financing to support the $2B revenue company. Before Numonyx, he served as chairman and CEO of ZiLOG, leading the successful turnaround of the business, public offering and ultimate sale to IXYS. Jim has served as an operator consultant to Texas Pacific Group (TPG), COO and Co-President of ON Semiconductor and led the buyout and IPO of ON.

Prior to ON Jim held various senior executive financial positions in the business units of National Semiconductor.

Mr. Thorburn is a former member of the Board of Directors for IXYS Corporation. He received his BSc (Hons.) in Agricultural Economics from the University of Glasgow and passed the Chartered Institute Management Accountant exams.

What is James M. Thorburn's net worth?

The estimated net worth of James M. Thorburn is at least $1.34 million as of August 17th, 2022. Mr. Thorburn owns 38,831 shares of Twist Bioscience stock worth more than $1,336,951 as of March 18th. This net worth approximation does not reflect any other investments that Mr. Thorburn may own. Learn More about James M. Thorburn's net worth.

How do I contact James M. Thorburn?

The corporate mailing address for Mr. Thorburn and other Twist Bioscience executives is 681 GATEWAY BLVD., SOUTH SAN FRANCISCO CA, 94080. Twist Bioscience can also be reached via phone at (800) 719-0671 and via email at [email protected]. Learn More on James M. Thorburn's contact information.

Has James M. Thorburn been buying or selling shares of Twist Bioscience?

James M. Thorburn has not been actively trading shares of Twist Bioscience during the last quarter. Most recently, James M. Thorburn sold 9,000 shares of the business's stock in a transaction on Wednesday, August 17th. The shares were sold at an average price of $48.51, for a transaction totalling $436,590.00. Following the completion of the sale, the chief financial officer now directly owns 38,831 shares of the company's stock, valued at $1,883,691.81. Learn More on James M. Thorburn's trading history.

Who are Twist Bioscience's active insiders?

Twist Bioscience's insider roster includes William Banyai (Insider), Robert Chess (Director), Keith Crandell (Director), Mark Daniels (Insider), Patrick Finn (Insider), Paula Green (SVP), Jan Johannessen (Director), Emily Leproust (CEO), James Thorburn (CFO), and Patrick Weiss (COO). Learn More on Twist Bioscience's active insiders.

Are insiders buying or selling shares of Twist Bioscience?

In the last year, Twist Bioscience insiders bought shares 1 times. They purchased a total of 10,000 shares worth more than $132,000.00. In the last year, insiders at the sold shares 5 times. They sold a total of 6,650 shares worth more than $238,840.00. The most recent insider tranaction occured on March, 6th when insider Dennis Cho sold 272 shares worth more than $10,180.96. Insiders at Twist Bioscience own 3.9% of the company. Learn More about insider trades at Twist Bioscience.

Information on this page was last updated on 3/6/2024.

James M. Thorburn Insider Trading History at Twist Bioscience

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/17/2022Sell9,000$48.51$436,590.0038,831View SEC Filing Icon  
5/23/2022Sell923$36.90$34,058.7044,463View SEC Filing Icon  
5/20/2022Sell6,620$36.02$238,452.4045,386View SEC Filing Icon  
4/14/2022Sell6,620$42.85$283,667.0046,688View SEC Filing Icon  
3/3/2022Sell3,517$52.35$184,114.95View SEC Filing Icon  
2/22/2022Sell4,442$52.52$233,293.84View SEC Filing Icon  
12/8/2021Sell7,000$89.37$625,590.00View SEC Filing Icon  
10/12/2021Sell8,000$101.76$814,080.00View SEC Filing Icon  
8/12/2021Sell6,000$103.70$622,200.0052,200View SEC Filing Icon  
7/21/2021Sell5,000$119.75$598,750.00View SEC Filing Icon  
6/8/2021Sell8,000$103.38$827,040.0054,732View SEC Filing Icon  
5/28/2021Sell6,000$110.00$660,000.0052,732View SEC Filing Icon  
4/22/2021Sell5,000$133.47$667,350.0053,034View SEC Filing Icon  
12/10/2020Sell20,018$149.11$2,984,883.9863,726View SEC Filing Icon  
9/8/2020Sell70,000$63.08$4,415,600.0081,719View SEC Filing Icon  
9/4/2020Sell30,000$63.58$1,907,400.0081,719View SEC Filing Icon  
8/19/2019Sell10,000$29.81$298,100.00View SEC Filing Icon  
See Full Table

James M. Thorburn Buying and Selling Activity at Twist Bioscience

This chart shows James M Thorburn's buying and selling at Twist Bioscience by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Twist Bioscience Company Overview

Twist Bioscience logo
Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels, primarily used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, the company provides synthetic SARS-CoV-2 RNA reference sequences as positive controls for the development of both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries used for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $33.83
Low: $32.87
High: $34.52

50 Day Range

MA: $36.67
Low: $32.28
High: $41.50

2 Week Range

Now: $33.83
Low: $11.46
High: $43.21

Volume

634,175 shs

Average Volume

995,473 shs

Market Capitalization

$1.96 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.64